Cadila Healthcare share price fell more than percent in the early trade on August 6 after the pharma company reported better numbers for the quarter ended June 2020.
On August 5 the company has posted 49.5 percent jump in its Q1 net profit at Rs 454 crore against Rs 303.6 crore and revenue was up 4.1 percent at Rs 3,640 crore versus Rs 3,496.3 crore.
Zydus Cadila announced that its plasmid DNA vaccine, ZyCoV-D, to prevent COVID-19 was found to be safe and well-tolerated in Phase I clinical trial. The company commences Phase II of the trials from August 6.
Nomura | Rating: Neutral | Target: Rs 370